Several years ago, a little-known drug named Ozempic—previously used only to treat diabetes—emerged as a promising new drug ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

Background: Despite their potential, Glucagon-like peptide-1 receptor agonists (GLP-1 RA ... left ventricular ejection fraction, and various drugs including ACEi, ARBi, ARNI, beta-blockers, and ...

A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.

Lipidated analogues of glucagon-like peptide 1 (GLP-1) have gained enormous attention as long-acting ... which greatly influences manufacturing and drug product development. This work provides a ...

Obesity is a growing concern worldwide, including in low- and middle-income countries (LMICs). Addressing this issue involves various strategies, including dietary and lifestyle changes, medical ...

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

Companies such as Teladoc and Omada Health have embraced GLP-1s while dangling the prospect of lowered costs to their ...

Glucagon-like peptide 1 receptor agonist use is not associated with an increased risk for thyroid cancer over the short term.

Cardinal Health had $210 billion in pharmaceutical and specialty drugs sales in fiscal 2024, up 11% year-over-year, helped in large part by GLP-1 sales. In Q4, segment sales rose 13% to $55 billion, ...

Several years ago, a little-known drug named Ozempic—previously used only to treat diabetes—emerged as a promising new drug ...